Navigation Links
RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean
Date:6/26/2008

Research that has yielded success in controlling certain errors in gene expression as a safer and more effective alternative to conventional drugs has won for Prof. Hermona Soreq, dean of the Faculty of Science at the Hebrew University of Jerusalem, one of this year's Kaye Innovation Awards.

The awards, presented annually during the Hebrew University's Board of Governors meeting, were presented on June 4 during the 71st meeting of the board.

The concept behind Prof. Soreq's work lies in coping with situations involving over or under expression of certain genes. Through development of state-of-the-art technologies, she and her research partners have succeeded in manipulating the RNA that translates cholinesterase genes from DNA into the cholinesterase proteins that control body-to-brain and brain-to body communication and are therefore very important.

Essentially, all the drugs known today are aimed at blocking the activities of proteins which are in excess in the body. This, says Prof. Soreq -- who is also the Slesinger Professor of Molecular Biology at the Hebrew University is "economically" wrong, because these drugs must target a large number of molecules (the proteins). This requires relatively large quantities of the required drugs, with the accompanying danger of unwanted side effects.

On the other hand, says Prof. Soreq, one doesn't want to hamper the genes that are at the top of the "pyramid" of the process leading to the production of the proteins, because this could endanger the next generation of cells to be produced. The third possibility, she continues, is to deal with the central part of the "pyramid" the RNA level. The RNA can be cloned and engineered to be expressed in various cells or tissues, adding protein if needed. Or, conversely, the RNA can be engineered to block a particular gene from being expressed, and thus prevent production of the unwanted excess of such protein.

Prof. Soreq's invention of engineered human cholinesterase and RNA-targeted agents to suppress its functioning has been patented by Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem. Over the years, this technology has won over $5 million in research grants and has generated a significant patent portfolio.

As an example of one way in which this manipulation can deal with protein excess or deficiency, Prof. Soreq cites the work being done by the PharmAthene Company in Annapolis, Maryland. This company, under license from Yissum, has developed a herd of goats which had been engineered to produce the human cholinesterase BCHE protein in their milk. PharmAthene, which has already signed a $219 million contract with the US Army to produce human BCHE for protection against nerve gas poisoning, has recently expanded its license with Yissum to include the use of BCHE for the treatment of Alzheimer's disease as well.

Another example of possible human application involves one of the protein variants produced from the closely related ACHE gene. The activity of this protein is blocked in persons who have suffered nerve gas poisoning. This human ACHE protein is now being produced under license from Yissum in engineered carrot cells developed by an Israeli company, Protalix, based in Carmiel.

A Tel Aviv startup, Ester Neurosciences, was established to exploit the promising technology developed by Prof. Soreq by developing a drug based on blocking the production of the ACHE protein in patients suffering from muscle weakening diseases.

EN101, the DNA-based lead compound utilizing this technology, has already been tested on patients with the auto-immune disease myasthenia gravis and has successfully reached phase II clinical trials. The results thus far suggest EN101 may have superior efficacy, longer duration of action, a more favorable side effect profile and dosing regimen, as compared with the currently used drug, which targets the protein. In December 2007, Ester Neurosciences was acquired by Amarin Corporation plc, a Nasdaq listed UK company.


'/>"/>

Contact: Rebecca Zeffert
rebeccaz@savion.huji.ac.il
972-025-881-641
The Hebrew University of Jerusalem
Source:Eurekalert

Related medicine news :

1. John & Jean Piety Named SLA Engineering Librarians of the Year
2. Chemical engineering researchers identify biofilms that cause infections
3. Scientists develop cyborg engineering for coronary bypass grafting
4. American Oriental Bioengineering Announces US$75 Million Share Repurchase Program
5. Carnegie Mellon engineering researchers automate analysis of protein patterns
6. Genetic Engineering and Biotechnology News reports on early ADMET use
7. Stratos Product Development Welcomes Back John Havard as Vice President of Engineering
8. Engineering students: Headset muffles loud, unnerving MRI noises
9. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
10. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
11. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... options at his office, Antoine Dental Center. Currently, patients can get single dental ... may apply, but patients can learn more about these offers by contacting Antoine ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could it ... the United States may be taken over by technology in the next five to ... over colleagues is drawing to a close. Success will belong to those who can ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management ... radiology marketing programs at the annual Building Better Radiology Marketing Programs conference, ... Hotel in Fort Worth, Texas. Nine awards are given out in five categories. They ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, 2017 the ... to withdraw previous guidance issued by the Obama Administration requiring schools to ... May 2016 by the Obama Administration came in response to a growing number ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... 23, 2017 Visiomed, the French leader ... 1997, is changing the landscape of healthcare with ... with pro-active, custom-made solutions. Recognizing the rising demand ... affordable healthcare without walls, Visiomed has launched BewellConnect, ... with healthcare professionals that is empowering the lives ...
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: